Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Alx Oncology Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners and 2 distinct art units. This distribution shows that each pending matter is being reviewed by a different individual, preventing any single examiner from controlling the portfolio's progress. The involvement of 2 distinct art units for 3 pending office actions suggests that the company's biotechnology and pharmaceutical filings are grouped into a few specific technical areas.
HUYNH, PHUONG N is the busiest examiner, managing 1 pending office action. Since there are 3 distinct examiners for 3 total actions, every examiner shares this workload level. Practitioners must navigate the preferences of 3 distinct examiners while also considering the collective practices of the 2 distinct art units. This structure requires a balanced approach to ensure that prosecution strategies remain consistent across the different technical areas involved. The presence of 3 pending office actions across 2 distinct art units indicates that at least one unit is handling multiple applications, which may allow for some administrative efficiency in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUYNH, PHUONG N | 1 | 65.8% | +53.6% |
| AGUIRRE, AMANDA L | 1 | 77.3% | +15.7% |
| LUNDE, GRACE HENRY | 1 | 63.0% | +38.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18326847 | COMBINATION THERAPIES FOR TREATING UROTHELIAL CARCINOMA | LUNDE, GRACE HENRY | 8d |
| 18540092 | CONSTRUCTS HAVING A SIRP-ALPHA DOMAIN OR VARIANT THEREOF | HUYNH, PHUONG N | — |
| 18559185 | EXATECAN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES THEREOF | AGUIRRE, AMANDA L | — |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18540092 | CONSTRUCTS HAVING A SIRP-ALPHA DOMAIN OR VARIANT THEREOF | HUYNH, PHUONG N | 1641 | §112DP | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18559185 | EXATECAN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES THEREOF | AGUIRRE, AMANDA L | 1626 | §103DP | Non-Final OA | — | Pending | Nov 06, 2023 |
| 18326847 | COMBINATION THERAPIES FOR TREATING UROTHELIAL CARCINOMA | LUNDE, GRACE HENRY | 1641 | §103Other | Non-Final OA | 8d | Pending | May 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlx Oncology Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Phuong N Huynh has the most, with 1 of Alx Oncology Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.